Literature DB >> 12391202

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

Weiguang Zeng1, Souravi Ghosh, Yuk Fai Lau, Lorena E Brown, David C Jackson.   

Abstract

In this study, we describe the synthesis of various lipopeptides based on the sequence of luteinizing hormone-releasing hormone (LHRH) and report on their abilities to induce Abs against this "self" hormone when inoculated into mice in the absence of additional adjuvant. The peptides consisted of a colinear CD4(+) T helper cell epitope from the L chain of influenza virus hemagglutinin and LHRH, which has B cell epitopes but no T cell epitopes present in its sequence. Lipids were attached either at the N terminus or between the T cell epitope and LHRH, in the approximate center of the peptide. The lipopeptide constructs displayed different solubilities and immunological properties that depended not only on the lipid content but also on the position of attachment of the lipids. Some of these constructs were highly immunogenic, inducing high titers of Ab, which were capable of efficiently sterilizing female mice when administered in saline by s.c. or intranasal routes. The most effective vaccines were highly soluble, contained the dipalmitoyl-S-glyceryl cysteine moiety, and had this lipid attached at the center of the molecule. The relative ability of the lipopeptides to induce an Ab response in the absence of external adjuvant was reflected by their ability to up-regulate the surface expression of MHC class II molecules on immature dendritic cells. These results demonstrate that the composition and position within peptide vaccines of self-adjuvanting lipid groups can influence the ability to induce the maturation of dendritic cells and, in turn, the magnitude of the resulting Ab response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391202     DOI: 10.4049/jimmunol.169.9.4905

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; Amber W McCall; Eng-Eong Ooi; Kanta Subbarao
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

3.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

Authors:  David C Jackson; Yuk Fai Lau; Thuy Le; Andreas Suhrbier; Georgia Deliyannis; Christina Cheers; Corey Smith; Weiguang Zeng; Lorena E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

4.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 5.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

Review 6.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.

Authors:  Xiuli Zhang; Annie Issagholian; Eric A Berg; Jordan B Fishman; Anthony B Nesburn; Lbachir BenMohamed
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.

Authors:  Weiguang Zeng; Kylie J Horrocks; Gorjana Robevska; Chinn Yi Wong; Kristy Azzopardi; Marija Tauschek; Roy M Robins-Browne; David C Jackson
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

9.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

10.  Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Immunome Res       Date:  2010-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.